See more : MMI Globale Aktier Akk. – Harding Loevner (MMIGAA.CO) Income Statement Analysis – Financial Results
Complete financial analysis of uniQure N.V. (0EE0.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of uniQure N.V., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- ADENTRA Inc. (ADEN.TO) Income Statement Analysis – Financial Results
- Fidelity Holding Corp. (FDHC) Income Statement Analysis – Financial Results
- Zota Health Care Limited (ZOTA.NS) Income Statement Analysis – Financial Results
- Tatia Global Vennture Limited (TATIAGLOB.BO) Income Statement Analysis – Financial Results
- Zenith Minerals Limited (ZNC.AX) Income Statement Analysis – Financial Results
uniQure N.V. (0EE0.L)
About uniQure N.V.
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.84M | 106.48M | 524.00M | 37.51M | 7.28M | 11.28M | 13.11M | 25.10M | 10.30M | 5.70M | 4.06M | 0.00 | 0.00 |
| Cost of Revenue | 13.63M | 3.34M | 24.98M | 122.40M | 94.74M | 73.06M | 67.41M | 72.69M | 638.49K | 43.58M | 1.10M | 13.49M | 0.00 |
| Gross Profit | 2.22M | 103.14M | 499.03M | -84.89M | -87.46M | -61.78M | -54.30M | -47.59M | 9.67M | -37.88M | 2.96M | -13.49M | 0.00 |
| Gross Profit Ratio | 13.98% | 96.86% | 95.23% | -226.28% | -1,201.15% | -547.47% | -414.30% | -189.62% | 93.80% | -664.91% | 72.82% | 0.00% | 0.00% |
| Research & Development | 214.86M | 197.59M | 143.55M | 122.40M | 94.74M | 74.81M | 72.38M | 72.51M | 51.15M | 41.26M | 18.20M | 13.53M | 20.09M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.04M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 74.59M | 55.06M | 56.29M | 42.58M | 33.54M | 25.31M | 25.04M | 26.00M | 21.12M | 13.58M | 16.06M | 6.04M | 4.93M |
| Other Expenses | -4.37M | -6.35M | -11.43M | -2.04M | 140.00K | 598.00K | 600.00K | -283.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 285.09M | 246.30M | 188.41M | 162.94M | 128.42M | 99.52M | 85.06M | 97.04M | 71.76M | 46.84M | 34.08M | 18.77M | 22.22M |
| Cost & Expenses | 298.71M | 249.64M | 213.38M | 162.94M | 128.42M | 99.52M | 85.06M | 97.04M | 72.40M | 46.84M | 35.18M | 18.77M | 22.22M |
| Interest Income | 19.56M | 609.00K | 162.00K | 938.00K | 3.55M | 2.73M | 117.00K | 70.00K | 600.22K | 203.07K | 140.85K | 29.10K | 90.73K |
| Interest Expense | 41.56M | 11.70M | 7.47M | 3.83M | 3.81M | 2.16M | 2.75M | 2.17M | 4.40M | 4.21M | 6.06M | 109.77K | 509.36K |
| Depreciation & Amortization | 11.90M | 8.54M | 7.30M | 10.65M | 6.60M | 6.90M | 7.54M | 6.09M | 4.86M | 1.87M | 738.77K | 724.73K | 764.69K |
| EBITDA | -253.10M | -108.02M | 319.00M | -126.97M | -113.79M | -74.01M | -69.74M | -63.97M | -72.48M | -45.71M | -33.71M | -18.09M | -22.63M |
| EBITDA Ratio | -1,597.55% | -125.85% | 60.67% | -303.46% | -1,523.47% | -647.71% | -486.56% | -286.66% | -549.67% | -685.76% | -762.25% | 0.00% | 0.00% |
| Operating Income | -282.87M | -143.16M | 310.62M | -125.43M | -121.14M | -88.23M | -71.96M | -71.95M | -74.82M | -41.14M | -31.12M | -18.77M | -22.22M |
| Operating Income Ratio | -1,785.46% | -134.44% | 59.28% | -334.34% | -1,663.78% | -781.92% | -549.00% | -286.66% | -726.12% | -722.18% | -765.72% | 0.00% | 0.00% |
| Total Other Income/Expenses | -23.69M | 14.90M | 22.19M | -16.02M | -3.06M | 5.16M | -8.12M | -283.00K | -12.11M | 3.37M | -4.57M | -694.32K | 2.79M |
| Income Before Tax | -306.56M | -128.26M | 332.81M | -141.44M | -124.20M | -83.07M | -80.59M | -72.23M | -78.62M | -45.04M | -37.03M | -19.46M | -22.42M |
| Income Before Tax Ratio | -1,934.97% | -120.45% | 63.51% | -377.04% | -1,705.82% | -736.20% | -614.85% | -287.79% | -762.98% | -790.61% | -911.32% | 0.00% | 0.00% |
| Income Tax Expense | 1.92M | -1.47M | 3.22M | -16.42M | 3.81M | 231.00K | -199.00K | 1.15M | -471.21K | 4.21M | 559.25K | 109.77K | 509.36K |
| Net Income | -308.48M | -126.79M | 329.59M | -125.02M | -128.01M | -83.30M | -80.39M | -73.37M | -78.15M | -45.04M | -37.03M | -19.46M | -22.42M |
| Net Income Ratio | -1,947.09% | -119.07% | 62.90% | -333.27% | -1,758.15% | -738.25% | -613.33% | -292.35% | -758.41% | -790.61% | -911.32% | 0.00% | 0.00% |
| EPS | -6.47 | -2.71 | 7.17 | -2.81 | -3.20 | -2.34 | -2.98 | -2.93 | -3.54 | -2.63 | -2.10 | -1.11 | -1.27 |
| EPS Diluted | -6.47 | -2.71 | 7.04 | -2.81 | -3.20 | -2.34 | -2.98 | -2.93 | -3.54 | -2.63 | -2.10 | -1.11 | -1.27 |
| Weighted Avg Shares Out | 47.67M | 46.74M | 45.99M | 44.47M | 40.00M | 35.64M | 26.98M | 25.04M | 22.06M | 17.12M | 17.59M | 17.59M | 17.59M |
| Weighted Avg Shares Out (Dil) | 47.67M | 46.74M | 46.84M | 44.47M | 40.00M | 35.64M | 26.98M | 25.04M | 22.06M | 17.12M | 17.59M | 17.59M | 17.59M |
Source: https://incomestatements.info
Category: Stock Reports